/
About Eton Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. We currently have eight commercial rare disease products: INCRELEX , ALKINDI SPRINKLE , KHINDIVI TM , GALZIN , PKU GOLIKE , Carglumic Acid, Betaine Anhydrous, and Nitisinone.
The business is unprofitable at the operating level (-1.06% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 104.9% YoY with margins expanding 5.6pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$87M
▲ +104.9% YoY
Net Income (TTM)
-$1M
▼ -20.4% YoY
Op. Margin
2.35%
▲ +5.6pp YoY
ROIC
2.83%
▲ +4.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$15M
▲ +980.7% YoY
Op. Cash Flow (TTM)
$16M
▲ +986.1% YoY
Net Debt
$12M
Cash & Equiv.
$20M
5Y CAGR: +359.6%
Continue Research